AIMS: Wearable cardioverter-defibrillators (WCDs) are indicated in patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy. Limitations of existing WCDs include poor compliance and high false alarm rates. The Jewel is a novel patch-WCD (P-WCD) that addresses these limitations with an adhesive-based design for near-continuous wear and a machine learning algorithm designed to minimize inappropriate detections. This was a first-in-human study of the Jewel P-WCD conducted in an electrophysiology (EP) lab to determine the safety and effectiveness of the device in terminating ventricular tachycardia/ventricular fibrillation (VT/VF) with a single shock. The aim was to evaluate the safety and effectiveness of terminating VT/VF with a single shock using the Jewel P-WCD. METHODS AND RESULTS: This was a first-in-human, prospective, single-arm, single-centre study in patients scheduled for an EP procedure in which VT/VF was expected to either spontaneously occur or be induced. The Jewel P-WCD was placed on consented patients; upon confirmation of VT/VF, a single shock (150 J) was delivered via the device. A group sequential design and Pocock alpha spending function was used to measure the observed proportion of successful VT/VF single-shock terminations. The endpoint was achieved if the lower confidence limit exceeded the performance goal of 62%, using a one-sided lower 97.4% exact confidence bound. Of 18 eligible subjects, 16 (88.9%, 97.4% confidence bound: 65.4%) were successfully defibrillated with a single shock, exceeding the primary endpoint performance goal with no adverse events. CONCLUSION: This first-in-human evaluation of the Jewel P-WCD demonstrated the safety and effectiveness of terminating VT/VF. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT05490459.

Department of Cardiology Na Homolce Hospital Prague Czech Republic

Division of Cardiology Department of Medicine University of California San Francisco 505 Parnassus Avenue San Francisco CA 94143 USA

Element Science Inc Redwood City CA USA

North American Science Associates Walnut Creek CA USA

Zobrazit více v PubMed

Wong  CX, Brown  A, Lau  DH, Chugh  SS, Albert  CM, Kalman  JM  et al.  Epidemiology of sudden cardiac death: global and regional perspectives. Heart Lung Circ  2019;28:6–14. PubMed

WHO Scientific Group, WHO . Sudden Cardiac Death: Report of a WHO Scientific Group. https://apps.who.int/iris/handle/10665/39554 (15 March 2024, date last accessed).

Bigger  JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary artery bypass graft (CABG) patch trial investigators. N Engl J Med  1997;337:1569–75. PubMed

Moss  AJ, Hall  WJ, Cannom  DS, Daubert  JP, Higgins  SL, Klein  H  et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med  1996;335:1933–40. PubMed

Buxton  AE, Lee  KL, Fisher  JD, Josephson  ME, Prystowsky  EN, Hafley  G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med  1999;341:1882–90. PubMed

Moss  AJ, Zareba  W, Hall  WJ, Klein  H, Wilber  DJ, Cannom  DS  et al.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med  2002;346:877–83. PubMed

Bardy  GH, Lee  KL, Mark  DB, Poole  JE, Packer  DL, Boineau  R  et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med  2005;352:225–37. PubMed

Piccini  JP, Allen  LA, Kudenchuk  PJ, Page  RL, Patel  MR, Turakhia  MP. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. Circulation  2016;133:1715–27. PubMed

Olgin  JE, Pletcher  MJ, Vittinghoff  E, Wranicz  J, Malik  R, Morin  DP  et al.  Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med  2018;379:1205–15. PubMed PMC

Olgin  JE, Lee  BK, Vittinghoff  E, Morin  DP, Zweibel  S, Rashba  E  et al.  Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses. J Cardiovasc Electrophysiol  2020;31:1009–18. PubMed PMC

Hummel  J, Ullery  S, Houmsse  M, Tomassoni  GF, Nair  D, Romero  J  et al.  Safety and Efficacy of the Jewel, a Novel Patch Wearable Cardioverter Defibrillator: Results from the Jewel Investigational Device Exemption Study. Philadelphia, PA: Featured Science Presentation at American Heart Association; 2023.

Pocock  SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika  1977;64:191–9.

Auricchio  A, Klein  H, Geller  CJ, Reek  S, Heilman  MS, Szymkiewicz  SJ. Clinical efficacy of the wearable cardioverter-defibrillator in acutely terminating episodes of ventricular fibrillation. Am J Cardiol  1998;81:1253–6. PubMed

Reek  S, Geller  JC, Meltendorf  U, Wollbrueck  A, Szymkiewicz  SJ, Klein  HU. Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks. Pacing Clin Electrophysiol  2003;26:2016–22. PubMed

Feldman  AM, Klein  H, Tchou  P, Murali  S, Hall  WJ, Mancini  D  et al.  Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol  2004;27:4–9. PubMed

Gleva  MJ, Sullivan  J, Crawford  TC, Walcott  G, Birgersdotter-Green  U, Branch  KR  et al.  Defibrillation effectiveness and safety of the shock waveform used in a contemporary wearable cardioverter defibrillator: results from animal and human studies. PLoS One  2023;18:e0281340. PubMed PMC

Zoll . LifeVest Model WCD 3000 Operator’s Manual. https://www.accessdata.fda.gov/cdrh_docs/pdf/P010030S056d.pdf (15 March 2024, date last accessed).

Kestra Medical Technologies Inc . ASSURE® Wearable Cardioverter Defibrillator (WCD) System Instructions for Use. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200037C.pdf (15 March 2024, date last accessed).

American Heart Association . Part 5: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing. Circulation  2005;112:35–46. PubMed

Winkle  RA, Mead  RH, Ruder  MA, Gaudiani  V, Buch  WS, Pless  B  et al.  Improved low energy defibrillation efficacy in man with the use of a biphasic truncated exponential waveform. Am Heart J  1989;117:122–7. PubMed

Fain  ES, Sweeney  MB, Franz  MR. Improved internal defibrillation efficacy with a biphasic waveform. Am Heart J  1989;117:358–64. PubMed

Gliner  BE, Jorgenson  DB, Poole  JE, White  RD, Kanz  KG, Lyster  TD  et al.  Treatment of out-of-hospital cardiac arrest with a low-energy impedance-compensating biphasic waveform automatic external defibrillator. The LIFE investigators. Biomed Instrum Technol  1998;32:631–44. PubMed

Bardy  GH, Gliner  BE, Kudenchuk  PJ, Poole  JE, Dolack  GL, Jones  GK  et al.  Truncated biphasic pulses for transthoracic defibrillation. Circulation  1995;91:1768–74. PubMed

Schmidt  AS, Lauridsen  KG, Adelborg  K, Torp  P, Bach  LF, Jepsen  SM  et al.  Cardioversion efficacy using pulsed biphasic or biphasic truncated exponential waveforms: a randomized clinical trial. J Am Heart Assoc  2017;6:e004853. PubMed PMC

FDA . Summary of Safety and Effectiveness Data (SSED): LifeVest Wearable Cardioverter Defibrillator. Silver Spring, MD: US Food and Drug Administration; 2015.

Poole  JE, Gleva  MJ, Birgersdotter-Green  U, Branch  KRH, Doshi  RN, Salam  T  et al.  A wearable cardioverter defibrillator with a low false alarm rate. J Cardiovasc Electrophysiol  2022;33:831–42. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05490459